CSF tau proteInS In dIFFerentIal dIagnoSIS oF deMentIa
ثبت نشده
چکیده
From a clinical standpoint, Alzheimer’s disease (AD) and frontotemporal lobar degeneration (FTLD) may be distinguished by a combination of clinical criteria and neuroimaging. However, in younger patients with mild cognitive deficits, it is sometimes difficult to classify patients based only on clinical findings, probably due to overlap of cognitive deficits with prominent executive and behavioral dysfunction, apraxia, and language disorders found in young AD patients [1]. Because of this overlap, it is crucially important to find new diagnostic tools to help clinicians to make an early and accurate diagnosis of a primary dementia. Previous studies on the diagnostic value of CSF total tau (t-tau) and phosphorylated tau (p-tau) proteins in differential diagnosis of early-onset AD and FTLD are variable. This is partly due to the wide range of tau protein concentrations found in postmortem brains of FTLD patients [2-4], but also due to large differences in age between the two groups [5]. To date, only few studies have evaluated CSF biomarkers between agematched AD and FTLD patients [6-8] and none evaluated CSF p-tau199. The aim of our study was to investigate the diagnostic value of total tau protein (t-tau), tau protein phosphorylated at threonine 181 (p-tau181) and tau protein phosphorylated at serine 199 (p-tau199) in agematched AD and FTLD patients.
منابع مشابه
Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia.
An ever increasing number of patients with neurodegenerative disorders calls for the evaluation of potential diagnostic markers that allow an early diagnosis and an early initiation of specific therapy. Clinical diagnosis of Alzheimer's disease (AD), the most common neurodegenerative disorder, reaches 80-90% accuracy upon autopsy in specialized clinical centers. Diagnosis of AD in early clinica...
متن کاملDifferential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.
BACKGROUND Phosphorylation of tau protein at threonine 231 (using full-length tau, 441 amino acids, for the numbering scheme) (p-tau(231)) occurs specifically in postmortem brain tissue of patients with Alzheimer disease (AD) and can be sensitively detected in cerebrospinal fluid (CSF). OBJECTIVES To determine to what extent CSF levels of p-tau(231) distinguish patients with AD from control s...
متن کاملCSF Biomarkers Profile in CADASIL—A Model of Pure Vascular Dementia: Usefulness in Differential Diagnosis in the Dementia Disorder
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is considered a model of pure vascular dementia (VD) because it occurs in young adults unlikely to have concomitant age and Alzheimer's Disease-(AD-) related pathology. CSF levels of β-amyloid 1-42 (Aβ42), total tau protein (t-tau), and phosphorylated tau-protein (p-tau), well accepted biomarker...
متن کاملDiagnostic Utility of CSF Tau and Aβ42 in Dementia: A Meta-Analysis
CSF tau and Aβ42 are considered as important markers to diagnose Alzheimer's disease in early stages. Hence, it is important to assess their status in different types of dementia. The main objective of this study was to assess whether these CSF biomarkers can be used to make the differential diagnosis of AD. In the present study, articles published from 1998 till 2009 were taken and meta-analys...
متن کاملCerebrospinal Fluid Biomarkers for Dementia with Lewy Bodies
More than 750,000 of the UK population suffer from some form of cognitive impairment and dementia. Of these, 5-20% will have Dementia with Lewy Bodies (DLB). Clinico-pathological studies have shown that it is the low frequency of DLB clinical core features that makes the DLB diagnosis hardly recognisable during life, and easily misdiagnosed for other forms of dementia. This has an impact on the...
متن کامل